Table 1.
Study characteristics.
| Author | Journal | Year | Institution | Country | Period | Design | Treatment | n | Pretreatment PSA (Median, ng/mL) | Initial Gleason Score (Median, Range) |
|---|---|---|---|---|---|---|---|---|---|---|
| Acar [15] | Ann Nucl Med | 2019 | Ataturk Training and Research Hospital | Turkey | 2015–2018 | R | 177Lu-PSMA I&T | 19 | NR | 9 (6–10) |
| Ahmadzadehfar [16] | J Nucl Med | 2017 | University Hospital Bonn | Germany | 2014–2016 | R | 223Ra | 13 | NR | 8 (6–10) |
| Grubmüller [17] | Eur J Nucl Med Mol Imaging | 2019 | Medical University of Vienna | Austria | 2015–2018 | R | 177Lu-PSMA 617 | 38 | 60.8 (IQR 15.4–264.2) | NR |
| Grubmüller [18] | The prostate | 2020 | Medical University of Vienna | Austria | 2015–2019 | R | 223Ra/cabazitaxel/docetaxel abiraterone/enzalutamide | 43 * | 11.3 (IQR 3.3–30.1) | NR |
| Gupta [19] | Urol Ann | 2019 | Rajiv Gandhi Cancer Insttute and Research Centre | India | NR | R | 177Lu-PSMA 617 | 23 | 66 (5.4–550) | 7 (6–9) |
| Hartrampf [20] | J Clin Med | 2020 | University Hospital Würzburg | Germany | 2014–2018 | R | docetaxel/cabazitaxel | 21 | 15.0 (0–800) | 8 (6–10) |
| Heinzel [21] | Eur J Nucl Med Mol Imaging | 2019 | university hospitals of Bonn and Aachen | Germany | 2014–2018 | R | 177Lu-PSMA 617 | 48 | NR | NR |
| Michalski [22] | Nuklearmedizin | 2019 | University of Freiburg | Germany | 2015–2018 | R | 177Lu PSMA-617 | 10 | 812.1 ± 972.4 | 8 (7–9) |
| Ozulker [23] | Rev Esp Med Nucl Imagen Mol | 2020 | Okmeydanı Training and Research Hospital | Turkey | 2017–2018 | R | docetaxel | 16 | 61.37 ± 102.2 | 8.50 ± 0.97 |
| Seitz [24] | Eur J Nucl Med Mol Imaging | 2018 | Technical University of Munich | Germany | 2013–2016 | R | docetaxel | 16 | 28 (2–3176) | ≤6: 1 7: 6 ≥8: 7 |
* 43 patients undergoing 67 systemic therapies; IQR = interquartile range; NR = not reported; PSA = prostate-specific antigen; R = retrospective.